The clinicopathological and genomic research of extranodal T-cell lymphoma in Japan
| Project/Area Number |
18K15101
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 49020:Human pathology-related
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | MEITL / SETD2 / JAK-STAT経路 / targeted NGS / 節外性T細胞性リンパ腫 |
|---|
| Outline of Final Research Achievements |
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare primary T-cell lymphoma of the digestive tract with poor prognosis. I aimed to clarify the genetic characteristics of MEITL in Japan using formalin-fixed paraffin-embedded tissue (FFPE). I demonstrated that mutations and/or loss of tumor suppressor gene SETD2 and mutations of genes associated with JAK/STAT pathway in MEITL. All these gene abnormalities might have pathogenic role of MEITL.
|
| Academic Significance and Societal Importance of the Research Achievements |
節外性に発生するT細胞性リンパ腫はいずれもまれな悪性リンパ腫で、未だ不明な点が多く、確立された治療法はない。今回、MEITLの遺伝子異常を明らかにすることができ、SETD2やJAK/STAT経路の異常が腫瘍発生に関与する可能性が示唆された。これらの遺伝子異常に基づき、有効な治療法が開発されることが望まれる。
|
Report
(3 results)
Research Products
(4 results)
